Arca
Skip to content
Tools
Tools

Pneumonia

Drug research and approvals for pneumonia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 599 studies of pneumonia are recruiting on ClinicalTrials.gov, Health Canada has authorized 16 drug trials for it since 2013, FDA has 6 approved and 14 open orphan designations naming it, and the EU has 14 authorised medicines for it.

  • Recruiting worldwide: 599
  • Trials authorized in Canada: 16
  • FDA orphan approvals: 6
  • EU medicines: 14

Recruiting now

Newest posted first, of 599 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 32

Phase 3 12 of 65

Phase 2 12 of 16

Phase 1 or earlier 12 of 15

How its trials ended

2,022 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 447 whose ending is known, 38% met their primary endpoint, 13% missed it and 48% stopped early.

  • Completed, result not reported84742%
  • Status unknown41521%
  • Ongoing31315%
  • Met its primary endpoint1729%
  • Stopped: other or unclear1387%
  • Missed its primary endpoint593%
  • Stopped: enrollment or feasibility362%
  • Stopped: lack of efficacy191%
  • Stopped: sponsor or business decision151%
  • Stopped: funding6<1%
  • Stopped: safety2<1%

Trials authorized in Canada

The 10 newest of 16; search them all in Canada trials
Sep 1, 2026Global unified adaptive research on acute care diseases –respiratory infections (guard-resp)DexamethasoneUniversity of ManitobaPending
Feb 26, 2026Microbiome-guided prophylaxis to reduce ventilator-associated pneumonia in intensive care units (micro-vap): a pilot randomized controlled trialTobramycin / Vancomycin / AztreonamGovernors of The University of CalgaryPending
Aug 26, 2024Targeting vascular inflammation in patients with community acquired pneumonia: a multi-centre, prospective, randomized control trialIcosapent ethyl / 18F-fluorodeoxyglucoseOttawa Heart Institute Research CorporationPending
Jul 17, 2024A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adjunctive recombinant human plasma gelsolin with standard…Recombinant human plasma gelsolin (rhu-pgsn)BioAegis TherapeuticsOngoing
Jan 3, 2024A randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of CAL02 administered intravenously in addition to…Cholesterol-sphingomyelin (CAL02)Eagle PharmaceuticalsOngoing
Jan 12, 2023Antithrombotic therapy to ameliorate clinical complications in community acquired pneumonia (attacc-cap)Heparin sodium / Lovenox / Fragmin / InnohepUniversity of ManitobaOngoing
Sep 15, 2022"a phase 1/2, multicenter, randomized, active-controlled, observer-blind, age de-escalation study to evaluate the safety, tolerability, and immunogenicity of…Pneumococcal 25-VALENT conjugate vaccine (ivt PCV-25)Inventprise Inc.Pending
Jul 28, 2022A phase 3 randomized, double-blind, active comparator-controlled, lot-to-lot consistency study to evaluate the safety, tolerability, and immunogenicity of V116…V116 (pneumococcal 21-VALENT conjugate vaccine) / PPSV23 (pneumococcal vaccine,…Merck & Co. (MSD)Ongoing
Apr 1, 2020Randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia (remap-cap)Heparin sodium / Lovenox / Fragmin / Innohep / Vitamin C / Simvastatin /…Unity Health TorontoOngoing
Sep 28, 2017A multicenter, randomized, double-blind, parallelgroup, clinical study of S-649266 compared with meropenem for the treatment of hospital-acquired bacterial…Cefiderocol (S-649266)/ MeropenemShionogiClosed

FDA orphan designations

Approved first, then open designations, newest first; 15 of 20
Jan 5, 1999MepronPrevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.Glaxo Wellcome Research and DevelopmentApproved
Dec 17, 1993NeutrexinConcurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients…Medimmune Oncology, Inc.Approved
Nov 25, 1992MepronFor the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to…Glaxo Wellcome Inc.Approved
Jun 15, 1989NebupentPrevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.Fujisawa USA, Inc.Approved
Mar 19, 1987RetrovirManagement of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed…Glaxo Wellcome Inc.Approved
Oct 16, 1984Pentam 300Treatment of Pneumocystis carinii pneumonia.Fujisawa USA, Inc.Approved
Jan 6, 2010Human monoclonal antibody directed against serotype O1…Treatment of pneumonia caused by serotype O1 positive Pseudomonas aeruginosaKenta Biotech LimitedDesignated
Nov 17, 2006Pafuramidine maleateTreatment of pneumocystis jiroveci pneumoniaImmtech Pharmaceuticals, Inc.Designated
Sep 18, 2006Human monoclonal antibody directed against serotype 011…Treatment of hospital acquired pneumonia caused by serotype 011 positive Pseudomonas aeruginosaKenta Biotech LimitedDesignated
Sep 18, 2006rSP-C surfactantFor use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen…Altana PharmaDesignated
Dec 20, 1993BeractantTreatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension…Ross LaboratoriesDesignated
Jul 23, 1993Primaquine phosphateFor use in combination with clindamycin hydrochloride in the treatment of Pneumocystis carinii pneumonia associated with AIDS.Sanofi Winthrop, Inc.Designated
Jan 8, 1992Dapsone USPFor the combination treatment of Pneumocystis carinii pneumonia in conjunction with trimethoprim.Jacobus Pharmaceutical CompanyDesignated
Dec 24, 1991Dapsone USPProphylaxis for Pneumocystis carinii pneumonia.Jacobus Pharmaceutical CompanyDesignated
Jan 28, 1991Cytomegalovirus immune globulin intravenous (human)For use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.Bayer CorporationDesignated

Medicines authorised in the EU

Newest first
Mar 24, 2025CapvaxivePneumococcal polysaccharide conjugate vaccine (21-valent)Merck Sharp & Dohme B.V.EMA ↗
Apr 22, 2024EmblaveoAztreonam; avibactamPfizer Europe MA EEIGEMA ↗
Mar 21, 2024ExblifepCefepime; enmetazobactamAdvanz Pharma LimitedEMA ↗
Feb 14, 2022Prevenar 20 (previously Apexxnar)Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Pfizer Europe MA EEIGEMA ↗
Dec 13, 2021VaxneuvancePneumococcal polysaccharide conjugate vaccine (adsorbed)Merck Sharp & Dohme B.V.EMA ↗
Jul 27, 2020XenletaLefamulinVenipharmEMA ↗
Jul 3, 2020VekluryRemdesivirGilead Sciences Ireland UCEMA ↗
Feb 13, 2020RecarbrioImipenem; cilastatin; relebactamMerck Sharp & Dohme B.V.EMA ↗
Dec 16, 2019QuofenixDelafloxacinA. Menarini Industrie Farmaceutiche Riunite s.r.l.EMA ↗
Nov 20, 2018VaboremMeropenem; vaborbactamMenarini International Operations Luxembourg S.A.EMA ↗
Jun 23, 2016ZaviceftaCeftazidime; avibactamPfizer Ireland Pharmaceuticals Unlimited CompanyEMA ↗
Sep 18, 2015ZerbaxaCeftolozane; tazobactamMerck Sharp & Dohme B.V.EMA ↗
Aug 22, 2012ZinforoCeftaroline fosamilPfizer Ireland PharmaceuticalsEMA ↗
Dec 9, 2009Prevenar 13Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)Pfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.